health – Page 4 – Market Industry Forecast News

Therapeutic Drug Monitoring Market Challenges: Overcoming Data Management Issues

The global therapeutic drug monitoring market size is estimated to reach USD 2.32 billion by 2030, expanding at a CAGR of 3.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. Recent technological advancements in the Point-of-Care (PoC) devices hold considerable transformative promises for the personalized predictive and preventive medicine. Therapeutic Drug Monitoring (TDM) forms a foundational part to the devising of personalized treatment plans for patients; and the advent of PoC diagnostic devices that yield quantitative measurements of the drug concentration plays a pivotal role in supporting the development of the precision medicine field in the healthcare sector. However, the broad application of the PoC devices for patient monitoring is still lagging behind. The presence of this untapped opportunity is one of the high impact rendering drivers for the market growth.

The employment of continuous therapeutic drug and metabolite monitoring in the early phase of the medication regimen, administered post-organ transplantation, forms a major application in the areas of critical care medicine and organ transplantation, which is expected to propel the growth of the therapeutic drug monitoring market over the forecast period. In addition, the imposing burden of diseases, such as epilepsy and cancer, the rising government initiatives, and the presence of high-unmet needs are some of the crucial determinants expected to further favor the emergence of this market.

Access the Therapeutic Drug Monitoring Market Size, Share & Trends Analysis Report By Product (Equipment, Consumables), By Drug Class (Antiarrhythmic Drugs), By End Use (Diagnostic Centers), By Region, And Segment Forecasts, 2024 – 2030

Therapeutic Drug Monitoring Market Report Highlights

The consumables segment covered over 65.4% of the market share in 2023 as a consequence of the extensive requirement of the consumables in the research laboratories and due to the repeat purchase of the kits and reagents.

The immunosuppressants segment is expected to grow fastest, with a compounded annual growth rate of 5.3% over the forecast period.

The hospital segment dominated the market share in 2023. In larger hospitals, various underlying technologies are employed to perform immunoassays; these comprise chemiluminescence, nephelometry, colorimetry, and fluorescence, which are available for the testing of a wide ranging drug panel.

The drug monitoring for the immunosuppressants is one of the fastest growing application segments owing to the introduction of novel TDM point-of-care testing devices for the evaluation of the concentration of administered immunosuppressants and the complementary metabolites, in order to achieve a prominent therapeutic effect while preventing drug toxicity events in patients that have undergone transplantations.

Key Therapeutic Drug Monitoring Company Insights

Some of the key companies in the therapeutic drug monitoring market are Abbott, ALPCO, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Chromsystems Instruments & Chemicals GmbH, F.Hoffmann-La Roche Ltd., Randox laboratories Ltd, Siemens Healthineers AG., and biomérieux, Inc. Organizations are focusing on increasing customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions and partnerships with other major companies.

Abbott, known for its diagnostic technologies, offers a range of products and solutions tailored to monitor drug levels in patients effectively. These include assays and instruments that aid healthcare providers in optimizing medication dosages, ensuring efficacy, and enhancing patient safety across various therapeutic areas.

ALPCO (American Laboratory Products Company) is a player in the therapeutic drug monitoring market, specializing in providing high-quality assays and immunoassay kits. These products are designed to accurately measure drug levels in patient samples, supporting healthcare providers in optimizing therapeutic outcomes and patient management.

Order your free sample copy of “Therapeutic Drug Monitoring Market Report 2024 – 2030, published by Grand View Research

Key Therapeutic Drug Monitoring Companies:

The following are the leading companies in the therapeutic drug monitoring market. These companies collectively hold the largest market share and dictate industry trends.

Abbott
ALPCO
Beckman Coulter, Inc
Bio-Rad Laboratories, Inc
Thermo Fisher Scientific Inc.
Chromsystems Instruments & Chemicals GmbH
F.Hoffmann-La Roche Ltd.
Randox laboratories Ltd
Siemens Healthineers AG.
biomérieux, Inc.

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Heart Attack Diagnostics Market Challenges: Addressing Barriers to Effective Diagnosis

The global heart attack diagnostics market size is expected to reach USD 18.52 billion by 2030, according to a new report by Grand View Research, Inc. The heart attack diagnostics market is anticipated to grow at a CAGR of 8.2% during the forecast year from 2024 to 2030. The overall risk factors and the disease burden remains large, thereby rendering the heart attack diagnostic sectors a profitable growth prospect. This growth is attributed to a majority of factors, such as high prevalence of coronary heart diseases, increased tobacco smoking, and obesity, enhanced adoption of unhealthy diet is resulting in a high cholesterol incidence in individuals, particularly in the rising geriatric population. However, the low Medicare reimbursement provided for the mobile cardiac outpatient telemetry electrocardiogram (ECG) and the progressively declining heart attack incidence rates are expected to hamper the market growth.

Access the Heart Attack Diagnostics Market Size, Share & Trends Analysis Report By Test (Electrocardiogram, Blood Test), By End-use (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2024 – 2030

The heart attack diagnostics market has been classified by product into electrocardiogram, which measures the electrical activity of the heart; echocardiogram, a form of ultrasound test that provides images of the heart; blood tests that measure the expression of certain proteins in excess, such as troponin levels, and cardiac enzymes; and other diagnostic products. The ECG segment is expected to witness a significant growth rate in developing countries, owing to the technological advances coupled with increasing applications of ECG. Although, the increasing demand for cost effective, rapid blood tests such as troponin and Creatine Kinase MB Isoenzyme (CK-MB) is likely to acquire major market share in the near future. The key countries landscape included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and Middle East. The Asia Pacific region is anticipated to be the fastest growing region during the forecast period. On the other hand, North America is estimated to dominate the global heart attack diagnostics market.

Heart Attack Diagnostics Market Report Highlights

North America is estimated to dominate the global heart attack diagnostics market. The increasing awareness about heart attacks, its causative and risk factors, and enhanced uptake and acceptance of technologically advanced diagnostics is expected to contribute to the market growth.

The Asia Pacific region is expected to be the fastest growing region during the forecast period. to The reason being the considerably large burden of heart diseases in certain developing regions, such as in India, where 2.4 million people die annually due to heart diseases. As a result of the soaring incidences of heart diseases, an urgent requirement to undertake awareness measures and incorporate advanced diagnostics is expected to fuel the market growth.

The Troponin segment dominated the blood tests market and accounted for a share of 62.5% in 2023. Troponin T, a protein present in the heart muscle, is crucial in diagnosing heart attacks through a high-sensitivity troponin T test.

Key Heart Attack Diagnostics Company Insights

The surge in competition is driving rapid technological progress, prompting companies to enhance their products through extensive research and development efforts. Leading companies are adopting various strategic approaches like mergers & acquisitions, partnerships, and new product introductions to increase their market presence.

Order your free sample copy of “Heart Attack Diagnostics Market Report 2024 – 2030, published by Grand View Research

Key Heart Attack Diagnostics Companies:

The following are the leading companies in the heart attack diagnostics market. These companies collectively hold the largest market share and dictate industry trends.

GE Healthcare
Hitachi Corporation
Koninklijke Philips NV
Midmark Corporation
F Hoffmann-La Roche Ltd
Schiller AG
Siemens Healthineers
Toshiba Corporation
Welch Allyn Inc
Astrazenca PLC

Recent Developments

In June 2024, Philips announced the launch of Philips Cardiac Workstation aims to transform diagnostic cardiology with introduction of new Cardiac Workstation, to enhance cardiology patients care and accelerate clinical decision making in Middle East and Africa (MEA) and Europe
In April 2024, GE Healthcare introduced Caption AI on Vscan Air SL to expand cardiac care access by allowing more clinicians/medical professional capture diagnostic-quality cardiac images.

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Fabry Disease Treatment Market Research: Key Findings on Drug Development and Usage

The global fabry disease treatment market size is estimated to reach a value of USD 4.93 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.9% from 2024 to 2030. Rising cohort of Fabry disease, increasing adoption of novel therapies such as chaperone treatment, and potential approval of pipeline drugs including substrate reduction therapies and enzyme replacement therapies are providing a fillip to the market.

Fabry disease is a rare inherited lysosomal storage disorder caused by genetic mutation that interferes with function of alpha galactosidase enzyme. Fabry disease generally has a late onset with mild symptoms, due to which several patients are often undiagnosed. Standard of care for management of the disease is enzyme replacement therapy (ERT). Sanofi’s Fabrazyme and Shire’s Replagal are the only approved ERTs in the EU; however in the U.S., only Fabrazyme has been approved.

Access the Fabry Disease Treatment Market Size, Share & Trends Analysis Report By Solution, By Treatment (Enzyme Replacement Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2030

Focus of current clinical trials is to improve the safety and efficacy profile of ERTs and introduction of novel oral therapies that can eliminate the need for intravenous infusions. Recently, Amicus Therapeutics’ Galafold has been approved as the first oral chaperone therapy for the treatment of adults in the U.S., Canada, EU, Japan, Australia, Israel, and South Korea.

North America held the largest share in the Fabry disease treatment market in 2017, followed by Europe. The growth of the region can be attributed to higher adoption of novel therapies, favorable reimbursement policies, and better healthcare facilities. However, high cost of therapy with ERTs such as Fabrazyme is an impediment for the market in developing regions.

Fabry Disease Treatment Market Report Highlights

Intravenous route dominated the market with a market share of 65.9 % in 2023 and is also expected to grow at the fastest CAGR over the forecast period from 2024 to 2030.

The enzyme replacement treatment segment dominated the market and accounted for a share of 72.3 % in 2023.

North America commanded the leading market share of more than 45.1% in the Fabry disease treatment market, followed by Europe, in 2023

APAC is likely to witness the fastest growth during the forecast period, followed by Latin America, due to increasing healthcare expenditure and rising patient population

Order your free sample copy of “Fabry Disease Treatment Market Report 2024 – 2030, published by Grand View Research

Key Fabry Disease Treatment Company Insights

Some of the key companies in the fabry disease treatment market include Sanofi S.A.; Shire PIc.; Amicus Therapeutics Inc.; ISU Abxis Co Ltd.;J CR Pharmaceuticals Co Ltd.; Protalix Biotherapeutics Inc.; and Idorsia Pharmaceuticals Ltd. The participants are involved in tactical strategy formation, creation of new treatments, and agreements aimed at achieving broad expansion and securing the top spot in the industry.

Sanofi S.A. healthcare companies are a culmination of a diverse group of companies collaborating on healthcare innovation. Also develops various treatments to treat numerous uncommon illnesses such as Fabry diseases. Amicus Therapeutics is a company that makes medicine for people with rare diseases. Amicus Therapeutics is focused on developing and expanding a pipeline of cutting-edge medicines for rare diseases such as fabry disease.

Key Fabry Disease Treatment Companies:

The following are the leading companies in the fabry disease treatment market. These companies collectively hold the largest market share and dictate industry trends.

Sanofi S.A.
Shire PIc.
Amicus Therapeutics Inc.
ISU Abxis Co Ltd.
JCR Pharmaceuticals Co Ltd.
Protalix Biotherapeutics Inc.
Idorsia Pharmaceuticals Ltd.
Avrobio Inc.
Takeda Pharmkceutical Co Ltd.
Chiesi Farmaceutici SpA
Freeline Therapeutics Holdings PLC
Yuhan Corp
MOP Therapeutics

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Functional Protein Market Players: Leading Companies and Their Competitive Strategies

The global functional protein market size is estimated to reach USD 9.48 billion 2030 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. Rising importance of protein-fortified convenience foods as a result of extensive advertising campaigns by nutraceutical suppliers in e-commerce portals and electronics media is expected to have a substantial impact. Furthermore, the increasing market penetration of powdered drink mixes as a result of product innovation by companies including General Foods Corporation is expected to play a crucial role in promoting the functional proteins consumption in the near future.

Whey protein isolates (WPI) accounted for 26.1% of global industry share in 2016. The segment is expected to witness significant gains owing to the introduction of the product forms in vanilla and chocolate flavors on a global level. Furthermore, increasing awareness towards enhancing muscular strength among athletes as well as gym professionals in emerging markets including Mexico, South Africa, China, and India is expected to broaden the application scope of WPI as sports nutrition goods over the next eight years.

Access the Functional Protein Market Size, Share & Trends Analysis Report, By Product, By Source (Animal Based, Plant Based), By Form (Dry, Liquid), By Application, By Region, And Segment Forecasts, 2024 – 2030

Functional Protein Market Report Highlights

Functional beverage segment is expected to witness the fastest CAGR over the forecast period. Rising importance of protein shakes for weight management amongst working class professionals as a result of endorsement by fitness experts to use functional beverage is expected to expand the industry size.

Dry form held the largest revenue share in 2023. Rising R&D spending towards the processing of spray-dried serum (SDS), spray-dried plasma (SDP) and globulin concentrate which are processed to use as colostrum supplements or replacers for feeding calves is expected to open the new avenues.

Asia Pacific is projected to witness high revenue growth at a CAGR of 36.8% in 2023. Significant gains in functional food & beverage production in China, India, and Malaysia as a result of favorable government policies including the reduction in import duties of consumables or equipment, to promote the foreign investments is expected to play a fundamental role in increase the fortification of functional nutrition ingredients.

Key Functional Protein Company Insights

Some key companies in the functional protein market include Abbott Nutrition; Kerry Group; and Fonterra Co-operative Group.

Abbott Nutrition offers a broad spectrum of products under various categories such as based on age, feeding route, product form (bar, liquid, powder), and dietary considerations. They offer medical food recipes catering to the needs of individuals with specific conditions.

Kerry Group offers functional foods in the dairy and non-dairy segment. Its broad spectrum of products includes plant-based as well as dairy-based food solutions, readymade and frozen foods, and meat and meat-based foods. Besides human consumption needs, they also operate in the animal and pet nutrition segment.

Order your free sample copy of “Functional Protein Market Report 2024 – 2030, published by Grand View Research

Key Functional Protein Companies:

The following are the leading companies in the functional protein market. These companies collectively hold the largest market share and dictate industry trends.

Abbott Nutrition
Amway Corporation
Archer Daniels Midland Company
Arla Foods Ingredients Group P/S
Cargill, Incorporated
DuPont de Nemours, Inc.
Fonterra Co-operative Group
FrieslandCampina
Glanbia plc
Kerry Group

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Drug And Gene Delivery Devices Market Demand Rises with New Treatments

The global drug and gene delivery devices market size is expected to reach USD 1.22 billion by 2030, registering a CAGR of 9.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising investment by the market players to develop innovative drug delivery systems to cater to the demand by the patients as well as to increase the bioavailability at minimum quantity of active pharmaceutical ingredient is driving the market growth. Additionally, increasing focus on R&D of gene delivery systems owing to the high growth potential of gene therapy for the treatment of a wide range of diseases is expected to fuel the market growth in the future.

Drug delivery systems are in a constant evolution along with the changing preference by the patient. For instance, initially, hormone replacement therapy was widely prescribed in the form of pills, whereas, it is now available in the form of prefilled syringes, patches, vaginal rings, gel, and sprays. The principal purpose of development of different forms of delivery systems is to increase the ease of use. Factors such as aesthetics of the delivery systems, price, and amount of API are also considered while designing the drug delivery system.

Access the Drug And Gene Delivery Devices Market Size, Share & Trends Analysis Report By Route Of Administration (Oral, Inhalation, Transdermal), By Vector (Viral, Non-Viral), By Region, And Segment Forecasts, 2024 – 2030

Drug And Gene Delivery Devices Market Report Highlights

In 2023, the oral segment dominated the market and accounted for the largest revenue share of 52.7%, owing to its convenience and ease of administration.

The injectable segment is expected to witness the fastest CAGR of 11.0% during the forecast period, fueled by increasing prevalence of life-threatening diseases and advancement in injectable drug delivery devices.

In 2023, North America dominated the drug and gene delivery devices market with a revenue share of 54.0%, owing to the rising number of people suffering from chronic diseases.

The drug and gene delivery devices market in Asia Pacific is projected to witness growth during the forecast period. The growth can be attributed to the increasing prevalence of chronic diseases such as heart disease, diabetes and cancer owing to the changing lifestyle, increase in consumption of alcohols and cigarettes.

Key Drug And Gene Delivery Devices Company Insights

Some of the key companies in the drug and gene delivery devices market include, Uniqure N.V.; Shanghai Sunway Biotech Co., Ltd; Pfizer, Inc.; Johnson and Johnson.

UniQure NV develops adeno-associated virus (AAV) based gene therapies with the help of its gene technology platform and offers treatments to patients suffering with severe genetic disorders.

Epeius Biotechnologies Corporation develops anti-cancer agents that eliminate metastatic disease.

Order your free sample copy of “Drug And Gene Delivery Devices Market Report 2024 – 2030, published by Grand View Research

Key Drug And Gene Delivery Devices Companies:

The following are the leading companies in the drug and gene delivery devices market. These companies collectively hold the largest market share and dictate industry trends.

Uniqure N.V.,
SiBiono GeneTech Co.
Epeius Biotechnologies Corporation
Shanghai Sunway Biotech Co., Ltd
Pfizer, Inc.
F. Hoffmann-La Roche Ltd.
Johnson and Johnson
Novartis AG
Bayer AG
Becton, Dickinson and Company

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Osteoporosis Drugs Market: Key Players Shaping the Future Landscape

The global osteoporosis drugs market size is expected to reach USD 18.80 billion by 2030 and is projected to grow at a CAGR of 3.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Access the Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2030

Osteoporosis Drugs Market Report Highlights

Branded drugs held the dominant share of the product segment in 2023. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy

Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies

In 2023, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics

Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care

The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Order your free sample copy of “Osteoporosis Drugs Market Report 2024 – 2030, published by Grand View Research

Key Osteoporosis Drugs Company Insights

Some key companies in the osteoporosis drugs market include Amgen Inc; Eli Lilly and Company; Merck & Co., Inc.; Novartis AG; GlaxoSmithKline plc; Pfizer Inc.; Radius Health Inc.; UCB S. A.; Teva Pharmaceuticals Industries Ltd. in the market are focusing on the development of osteoporosis drugs to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives.

Amgen Inc. develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicine for treating cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders, and nephrology conditions.

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent-protected prescription medicines, generic pharmaceuticals, and biosimilars.

Key Osteoporosis Drugs Companies:

The following are the leading companies in the osteoporosis drugs market. These companies collectively hold the largest market share and dictate industry trends.

Amgen Inc.
Eli Lilly and Company
Merck & Co., Inc.
Novartis International AG
Pfizer Inc.
GlaxoSmithKline plc
Radius Health, Inc.
UCB S.A.
Teva Pharmaceutical Industries Ltd.
Roche Holding AG

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

CIS Insulin Market: The Impact of COVID-19 on Diabetes Care

The CIS insulin market size is expected to reach USD 4.67 billion by 2030, registering a CAGR of 5.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of an extensive pipeline portfolio of products exhibiting higher efficacies and their subsequent commercialization over the next six years is expected to serve this market as a high impact rendering driver. The introduction of government initiatives aimed at improving the affordability of insulin via price reduction, such as the collaboration between the government of Ukraine and Indar to reduce the price of insulin by 20% in 2013 is expected to have positive influence on demand. Some of the other drivers of this market include increasing attempts made by manufacturers to capitalize on the untapped opportunities by opening new manufacturing units to improve the supply of insulin and growing incidence rates of type II diabetes are some of the factors expected to fuel future market growth.

Access the CIS Insulin Market Size, Share & Trends Analysis Report By Product, By Type (Human Insulin, Insulin Analog), By Application (Type 1 Diabetes), By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2030

CIS Insulin Market Report Highlights

Poland CIS Insulin market held a substantial market share of 10.3% in 2023 due to various factors influencing market growth, including drivers, constraints, opportunities, and threats

Long-acting Insulin dominated the market and accounted for a share of 52.7% in 2023. Long-acting insulins mimic natural insulin with a slower onset of action and are mainly utilized as basal insulins.

Type 1 Diabetes dominated the market and accounted for a share of 79.6% in 2023. Type 1 diabetes primarily affects children, teenagers, and some adults. Type 2 Diabetes is expected to register the fastest CAGR of 11.6% during the forecast period, driven by the increasing prevalence of the condition in the CIS region.

Insulin analog led the market with the largest revenue share of 89.0% in 2023. Insulin analogs are a form of engineered insulin that starts working quickly and has an instant impact on the body’s functions.

Key CIS Insulin Company Insights

Leading insulin manufacturers are adopting strategies such as new product launches, partnerships, and mergers to increase market share. The arrival of biosimilar insulin has created opportunities for new players. Governments in the CIS region are providing support to local producers, encouraging multinational companies to set up production units. Investments in R&D are also driving innovation in insulin drugs and devices.

Order your free sample copy of “CIS Insulin Market Report 2024 – 2030, published by Grand View Research

Some of the key companies in the CIS Insulin market include

Novo Nordisk A/S focuses on developing, manufacturing, and selling pharmaceutical products. The company specializes in providing diabetes care, including insulin delivery systems and various other diabetes products. Novo Nordisk is also active in fields such as managing haemostasis, treating growth disorders, and providing hormone replacement therapy.

Eli Lilly and Company, a pharmaceutical company transforms scientific research into treatments to improve the lives of individuals globally. By utilizing biotechnology, chemistry, and genetic medicine, company is pushing the boundaries of science to address major global health issues.

Key CIS Insulin Companies:
Eli Lilly and Company
Sanofi S.A.
Boehringer Ingelheim International GmbH
Oramed Pharmaceuticals Inc.
Novo Nordisk A/S
Merck & Co., Inc.
Bristol-Myers Squibb Company
Novartis AG

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Biotech Flavor Market: Addressing Challenges in Flavor Production

The global biotech flavor market size is expected to reach USD 2.45 billion by 2030, expanding at a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing awareness regarding nutritional benefits such as stimulation of appetite and content of citric acid to boost immune and rising health consciousness are expected to drive the market in the next few years.

Growing penetration of natural flavoring due to advancement in various types of beverages has been driving the demand for the global market. Beverages infused with biotech flavors help in boosting energy level, metabolism, and other bodily functions. Flavors such as lemon and cucumber help in stimulating liver functions and strengthening veins. Growing trend of convergence between biotech and nutraceuticals driven by increasing application of ingredients claims to have various health benefits. For instance, Robertet introduced Xtreme Flavors with high impact, true fruit, authentic, and natural flavoring that can be infused in various beverage preparations. Some of the flavors include plum and plum sugar, pear, watermelon, and apple.

Access the Biotech Flavor Market Size, Share & Trends Analysis Report By Type (Vanilla, Fruity Flavor, Others), By Form (Liquid, Powder, Paste), By Application, By Region, And Segment Forecasts, 2024 – 2030

The powder form held the largest market share and generated a revenue of USD 17.1 billion in 2018. This segment consists of energy drinks powder, yogurt powder, butter powder, and others with features that are applicable in maintaining health. The liquid form is expected to expand at a CAGR of 7.4% over the forecast period. Growing awareness and popularity of liquid form due to its wide usage in beverages such as fruits and vegetables juices, energy drinks, and sodas with the respective taste preference is the key factor driving the segment demand.

Vanilla flavor accounted for the largest market share with a revenue of USD 17.8 in 2018. This flavoring is mostly used in food products due to its benefits such as powerful antioxidant, antibacterial, anti-inflammatory, and cholesterol stabilizers. Fruity flavor is expected to register a CAGR of 7.3% in the forecast period due to increased application in the form of jams and growing research and development expenditure in the respective market. Consumers are demanding healthier options for food spreads and fillings, which, in turn, has driven the demand for fruity flavors. Major market players have been significantly carrying out research and development to make these products available according to the needs of consumers. For instance, IFF Inc. derives natural ingredients from flowers, fruits, and botanical products with the help of specialized drying technology by eliminating water with best taste, nutrition, and color matrix intact in juice drinks, carbonated beverages, candy chewing gum, yogurt, ice cream, and cheese.

North America was the largest regional market with a revenue of USD 14.2 billion in 2018. The region is expected to maintain its lead over the forecast period. Increasing preference for healthy ready to eat and drink products in U.S. is expected to drive the companies to develop more of biotech flavor infused consumables. Growing consumption of packaged food is another driver for the market growth in the region. Key players in the global market include Givaudan; Firmenich SA; IFF Inc.; Symrise AG; Wild Flavors; Takasago International Corporation; Mane Flavors; Frutarom; Sensient Technology Ltd.; and Roberetet.

Biotech Flavor Market Report Highlights

· By type, fruity flavor is expected to register a CAGR of 9.0% from 2024 to 2030

· The powder segment accounted for the largest market revenue share in 2023.

· North America dominated the biotech flavor market with a revenue share of 39.6% in 2023.

· Asia Pacific Biotech Flavors market is anticipated to witness significant growth in the biotech flavor market.

· The biotech flavor market is highly competitive in nature due to presence of the main players including Givaudan

· Various manufacturers are concentrating on new product launches and capacity expansion to estimate existing and future demand patterns from upcoming product segments.

Order your free sample copy of “Biotech Flavor Market Report 2024 – 2030, published by Grand View Research

Key Biotech Flavor Company Insights

Some of the key companies in the biotech flavor market include Givaudan SA, Firmenich SA, Symrise AG, International Flavors & Fragrances Inc. (IFF), Takasago International Corporation, Sensient Technologies Corporation, Kerry Group plc, Bell Flavors & Fragrances Inc., and Flavorchem Corporation. Vendors in the market are focusing on increasing customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies.

Firmenich SA offers high-quality fragrances, flavor components, and oral care items. The company’s offerings in the biotech flavor space include a sequence of innovative ingredients designed to provide customers with essential nutrients, catering to the growing interest in natural, sustainable, and clean-label products.

Givaudan SA’s biotech flavor offerings are built upon its molecular biology, fermentation technology, and expertise in extracting natural ingredients. The company specializes in developing flavors through microbial fermentation and enzymatic transformation, allowing the production of authentic and sustainable flavor profiles. These biotech flavor are designed to meet stringent regulatory standards and consumer preferences for clean-label products that are natural, transparent, and free from synthetic additives.

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Hydrogel-based Drug Delivery System Market Key Insights: Navigating Emerging Trends

The global hydrogel-based drug delivery system market size is anticipated to reach USD 11.77 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.7% from 2024 to 2030. Hydrogels help in achieving spatial and temporal control over the release of the incorporated drug. Therefore, the surging demand for controlled releases drug delivery system across many therapeutic areas is a key factor expected to contribute to market growth during the forecast period.

Hydrogel-based drug delivery systems deliver the therapeutic drug directly at the target site and in a sustained manner. This can leverage beneficial outcomes such as improved efficacy, reduced side effects, and decreased dosage for patients and formulators. Hydrogel-based drug delivery systems are appealing and have been used in many branches of medicine such as oncology, pain management, immunology, cardiology, and wound management.

Access the Hydrogel-based Drug Delivery System Market Size, Share & Trends Analysis Report By Polymer Origin (Natural, Synthetic, Hybrid), By Delivery Route, By Region, And Segment Forecast, 2024 – 2030

The unique physical properties of hydrogel attract their interest in use for drug delivery applications. The porosity and drug loading capacity of hydrogels can be adjusted by modifying the density of cross-linking. This helps them to protect liable large drug molecules from degradation increasing the half-life. Many research studies have been carried out to examining the delivery of insulin orally using hydrogel systems. As patient compliance issues are frequently reported with injectable insulins such innovation is expected to be a disruptive technology in the diabetes care market.

There are numerous clinical studies underway specific to hydrogel-based drug delivery systems and various hydrogel technologies have already received regulatory approval for biomedical application. However, the technological challenges including the absence of defined regulatory guidelines, chemistry, complex manufacturing and control paraments, and practical adaptability are major roadblocks in the successful implementation in drug delivery use. For instance, the fabrication of hydrogel is complex and varies significantly depending upon the hydrogel systems.

Hydrogel-based Drug Delivery System Market Report Highlights

Based on polymer origin, the synthetic segment held the largest proportion of market share in 2023

The hybrid segment is expected to witness the fastest growth rate over the forecast period owing to the development of stimuli-responsive hydrogel technology

The synthetic segment is anticipated to grow fast over the forecast period compared to natural hydrogels due to their high drug loading capacity and improved mechanical strength

Based on delivery route, the ocular segment accounted for the largest revenue share in 2023

The subcutaneous segment is expected to grow at a healthy rate over the forecast period owing to the increasing number of clinical and pre-clinical studies carried out

North America holds the largest revenue share in this market due to the presence of key companies in the region doing R&D on specific hydrogel-based drug delivery systems

In Asia Pacific, the market is expected to grow at the fastest rate over the forecast period due to large patient base, improving healthcare infrastructure, and surging demand for modern therapies

Order your free sample copy of “Hydrogel-based Drug Delivery System Market Report 2024 – 2030, published by Grand View Research

Key Hydrogel-based Drug Based Delivery System Company Insights

Some key companies in the market include GALDERMA; Blairex Laboratories, Inc.; Johnson & Johnson; Bausch + Lomb; Medtronic; and Ocular Therapeutix, Inc. Vendors in the market are focusing on increasing their customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other emerging and prominent industry participants.

Ocular Therapeutix, Inc., is a biopharmaceutical company that specializes in creating, advancing, and marketing new treatments for eye disorders. It employs its own bioresorbable hydrogel-based formulation technology, ELUTYX. The company has manufacturing facilities in Massachusetts.

Blairex Laboratories, Inc., a global pharmaceutical company, delivers products related to the consumer and pharmaceutical industry. Some of the company’s major offerings are sterile saline solutions and contact lens care.

Key Hydrogel-based Drug Delivery System Companies:

The following are the leading companies in the hydrogel-based drug delivery system market. These companies collectively hold the largest market share and dictate industry trends.

GALDERMA
Blairex Laboratories, Inc
Johnson & Johnson
Bausch + Lomb.
Medtronic
Ocular Therapeutix, Inc.
Ferring B.V.
Endo, Inc.
Tolmar Inc

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Military Wearable Medical Devices Market Key Insights: Navigating Emerging Trends

The global military wearable medical devices market size is expected to reach USD 38.77 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 26.3% from 2024 to 2030. The growth of the market is attributed to the improvement in the overall performance of military soldiers with the help of innovative technology and the rising demand for lightweight military devices.

The Covid-19 pandemic has transformed the market for military wearable medical devices because wearable technologies could monitor, detect, and prevent the spread of the virus. The Covid-19 virus has indirectly increased the demand for wearable medical devices. According to the WHO guidelines, viral infection mainly spreads through the eyes, nose, and mouth and it is difficult to identify the virus during the initial days of contract. Hence, with the innovative technology, the individual can regularly check and monitor their body temperature, oxygen level, heart rate, and body performance so that if they found any negative result, then they can immediately take precautions and treatment.

Access the Military Wearable Medical Devices Market Size, Share & Trends Analysis Report By Application (Heart, Performance Monitor), By Region (North America, Europe, Asia Pacific), And Segment Forecasts, 2024 – 2030

As soldiers have to train and work in a rough and harsh environment, the wearable device they are carrying must be lightweight and must provide full information of the soldier’s health and performance. Many market players are developing and introducing such wearable devices, which can bear the toughest environment of the battlefield. With the help of the device, armed forces can track and monitor the sleep of every individual, circadian stability, and all physical activity so that they can make necessary changes for better results as per the data.

As per the soldier modernization program, the military has decided to opt for lightweight wearable devices as soldiers already have to carry heavy stuff with them and such devices can increase the speed of the movement. The devices should be easy to carry and made of the toughest material to adapt to the environment. These devices should result in the betterment of the overall performance of the individuals.

Military Wearable Medical Devices Market Highlights

By application, the heart monitor segment held the largest revenue share in 2023 as the system directly detects any uncertain change in the health of an individual, and the patient can be treated as early as possible

North America led the market in 2023 and is expected to maintain its lead over the forecast period owing to technological advancements and increasing R&D investment in military devices

Asia Pacific is expected to witness the fastest growth over the forecast period due to the rising cardiovascular events in the region and rising healthcare spending

The industry is highly competitive with players who are developing advanced medical devices for the soldiers that can be used in war zones or in extreme environments

Order your free sample copy of “Military Wearable Medical Devices Market Report 2024 – 2030, published by Grand View Research

Key Military Wearable Medical Devices Company Insights

Some key companies in the market include Samsung, Bittium, Garmin, Apple Inc., Fitbit, and GOQii. Companies are focusing on longer battery life, connectivity, and accurate readings in the devices.

Garmin has been deploying products in segments such as automotive, marine, aviation, sports & outdoor with a focus on rugged use and long battery life providing a wide range of services through their devices such asMulti-GNSS Support, ABC sensors, trackback routing, geocaching, point-to-point navigation, compass, GPS compass.

Apple Inc. monitors heart rates, fall detection, blood oxygen level, and AFib history with the help of an electrical heart sensor in their product.

Key Military Wearable Medical Devices Companies:

The following are the leading companies in the military wearable medical devices market. These companies collectively hold the largest market share and dictate industry trends.

Bittium
Polar Electro
Oura
Garmin
NeuroMetrix
GOQii
Apple Inc.
Samsung
Fitbit
Zephyr Technology Corporation
Camntec

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com